Login to Your Account

Protease in the hole: Latest Targacept fizzle clears deck for nearing Catalyst merger

By Randy Osborne
Staff Writer

Thursday, April 16, 2015

On the heels of last summer's phase IIb failure of TC-5214 in overactive bladder and a string of other duds with neuronal nicotinic receptors, Targacept Inc. said top-line results from a phase I/II exploratory study of TC-6499 as a treatment for diabetic gastroparesis also missed its primary endpoint and the program will be discontinued.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription